Merck-backed Organon completed the acquisition of Alydia Health for $240m.

Merck-backed Organon, a pharmaceutical company, completed the acquisition of Alydia Health, a commercial-stage medical device company, for $240m, including $215m upfront plus a $25m contingent milestone payment. “The acquisition aligns with Organon’s strategy to become a global leader in women’s health by focusing our product development on her unmet medical needs. We believe that Organon’s strong global commercial footprint in reproductive health, in conjunction with Alydia’s rapidly growing commercial capabilities in the US, will help enable growth of the Jada® System, including potential expansion into Europe and other developed countries, as well as in the world’s least developed markets where Organon has significant experience creating affordable access,” Kevin Ali, Organon CEO.